What it is
Kisspeptin is not a man-made drug. It is a family of natural human hormones made from a gene called KISS1. The gene makes a long protein that the body cuts into shorter pieces. The longest piece in common use is 54 amino acids long and is called kisspeptin-54 (older papers call it metastin). The shortest is the last 10 amino acids of that chain, called kisspeptin-10. Amino acids are the building blocks of proteins. All the pieces end in the same ten amino acids, which is the part that fits the receptor.
More on what it is and where it came from
The two forms behave very differently in the body. Kisspeptin-54 stays in the blood far longer: its half-life (the time for the blood level to fall by half) was measured at about 28 minutes in healthy men. Kisspeptin-10 is cleared almost at once, with a half-life of about 4 minutes in the same group of researchers' hands. Most of the human trials that produced a useful result, including all the IVF work, used kisspeptin-54. Kisspeptin-10 is the form usually sold online.
No kisspeptin product is an approved medicine in any country. The FDA could find no approved product containing kisspeptin-10 anywhere in the world, and no monograph for it in the US, European or Japanese pharmacopoeias. Everything described on this page comes from research studies, most of them small, most of them designed to answer questions about how the body works rather than to show that a treatment helps patients.
The KISS1 gene was found in 1996 by cancer researchers in Hershey, Pennsylvania, who were looking for genes that stop tumours spreading; the name comes from Hershey's Kisses. In 2001 three groups showed that the gene's peptide products are the natural partners of an until-then orphan receptor called GPR54 (now also called KISS1R). The link to reproduction came in 2003, when two independent teams, one in Paris led by Nicolas de Roux and one centred on Massachusetts General Hospital and Cambridge led by Stephanie Seminara and William Crowley, found that people who inherit two broken copies of the receptor gene fail to go through puberty. From about 2005 onwards a group at Imperial College London led by Waljit Dhillo, with Channa Jayasena, Ali Abbara and Alexander Comninos, ran most of the human studies, and the Massachusetts General Hospital group led by Stephanie Seminara and Yee-Ming Chan ran most of the rest.
How it is thought to work
The reproductive system runs on a chain of signals. Nerve cells in the hypothalamus, at the base of the brain, release a hormone called GnRH in short pulses. GnRH tells the pituitary gland to release two hormones, LH and FSH. Those travel in the blood to the ovaries or testes, which then make oestrogen or testosterone and mature eggs or sperm. Kisspeptin sits one step above GnRH: kisspeptin nerve cells switch the GnRH cells on. FDA's own review describes kisspeptin as an upstream regulator of GnRH secretion.
More on how it works
That is why the 2003 genetic findings mattered so much. If the receptor for kisspeptin does not work, the GnRH pulses never get going properly, and puberty does not happen. Giving kisspeptin to a healthy volunteer does the reverse: within minutes LH rises, because the GnRH cells have been prodded.
The catch is that the switch is built for pulses, not for a steady signal. In monkeys, a continuous infusion produced an LH surge that lasted only about three hours before levels fell back to baseline despite the infusion continuing. The same thing happens in people. Researchers call this tachyphylaxis: the response fades when the stimulus does not stop. Pulsed or intermittent exposure keeps working much better than continuous exposure. This is a well-described limitation, not a theory.
What is established in people
What is established is narrow but solid: kisspeptin is the switch that turns on the reproductive hormone axis, and giving it to people raises LH and FSH within minutes, more strongly in men than in women, and in women only at certain points in the menstrual cycle. What is not established is that it treats anything. The most advanced work is kisspeptin-54 as an egg-maturation trigger in IVF, tested in trials of 53 and 60 women at a single London centre, open-label and without a head-to-head comparison against the standard trigger. The brain-imaging and sexual-desire trials in people with hypoactive sexual desire disorder were small single-exposure crossover studies measuring brain activity, not treatment trials. In the group most often invoked online, men whose reproductive axis has failed, kisspeptin produced no response at all. Repeated or continuous exposure loses its effect within days to weeks. Total human exposure is in the low hundreds of people, almost always for a day or less; the longest published study ran for 12 days. No kisspeptin medicine is approved anywhere.
What the studies found
18 studies, human trials first. Each links to the paper or registry record.
- Human trial2026
Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men
The most recent human study of the form usually sold, and the longest.
Full finding, who was studied, and limits
Who: 15 healthy men across three parts (7, 4 and 7 men), with 12 men as controls. Randomised, single-blinded, placebo-controlled. The three parts were an 8-hour infusion, a continuous 5-day infusion, and a daily on-off infusion pattern for 12 days.
The most recent human study of the form usually sold, and the longest. Short infusions raised LH, FSH and testosterone compared with vehicle (P less than 0.0001). Continuous infusion for 5 days kept testosterone up but the gonadotropin levels ended up no different from vehicle, so that effect was lost. The on-off pattern over 12 days did keep working, but less well: the LH rise over vehicle was 1.68 on day 1 and 1.14 on day 12 (P equals 0.003 against vehicle). After 12 days a fresh injection still raised gonadotropins, so the receptor was still working.
Read with care: Fifteen men, three different protocols, so each arm is very small. Twelve days is still short. It confirms that continuous exposure loses the gonadotropin effect and that even an intermittent pattern fades somewhat. No clinical outcome was measured.
European Journal of Endocrinology 2026;195(2):206-216 · pubmed.ncbi.nlm.nih.gov
- Human trial2025
Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans.
Kisspeptin-54 given by the non-injected method named in the title raised LH (the pituitary hormone that drives the testes and ovaries) in every group compared with placebo: average extra rise 3.1 units per litre in healthy men (p = 0.002), 1.0 in healthy women (p = 0.004) and 4.3 in women with hypothalamic amenorrhoea (p < 0.001).
Full finding, who was studied, and limits
Who: Kisspeptin-54. 12 healthy men, 12 healthy women and 10 women with hypothalamic amenorrhoea (periods stopped because the brain's signal to the ovaries is switched down), in a randomised, double-blind, placebo-controlled crossover study (each person had both kisspeptin and placebo on different days). Plus lab stability tests and mouse work. Run at Imperial College London; funded by the UK National Institute for Health and Care Research and the Medical Research Council.
Kisspeptin-54 given by the non-injected method named in the title raised LH (the pituitary hormone that drives the testes and ovaries) in every group compared with placebo: average extra rise 3.1 units per litre in healthy men (p = 0.002), 1.0 in healthy women (p = 0.004) and 4.3 in women with hypothalamic amenorrhoea (p < 0.001). No side effects or adverse events were seen. In mice, labelled kisspeptin collected in the lining of the nose, where hormone-controlling nerve cells carry kisspeptin receptors.
Read with care: Small groups and single doses on study days; it measured hormone rises over a few hours, not fertility, periods or any longer-term effect. The research group has led most kisspeptin work in people and two authors consult for Myovant Sciences, outside this work.
- Human trial2025
Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans.
Kisspeptin raised LH strongly (p < 0.001), showing it was active, but compared with placebo it did not change anxiety on a standard questionnaire (p = 0.13), stress hormone cortisol (p = 0.73), blood pressure or heart rate.
Full finding, who was studied, and limits
Who: Kisspeptin-54. 95 healthy adults (63 men, 32 women, average age 31) in a double-blind, randomised, placebo-controlled crossover study: each had a 75-minute kisspeptin session and a placebo session in random order. Run at Imperial College London.
Kisspeptin raised LH strongly (p < 0.001), showing it was active, but compared with placebo it did not change anxiety on a standard questionnaire (p = 0.13), stress hormone cortisol (p = 0.73), blood pressure or heart rate. Animal studies had given conflicting answers on whether kisspeptin raises or lowers anxiety.
Read with care: Healthy volunteers and a single 75-minute session; it cannot speak to repeated or long-term use or to people with anxiety disorders. From the same research group that develops kisspeptin treatments.
Journal of Clinical Endocrinology and Metabolism · pubmed.ncbi.nlm.nih.gov
- Human trial2025
Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans.
A new use under study: a possible test for oxytocin deficiency (low levels of the hormone oxytocin, seen in some people with a pituitary condition).
Full finding, who was studied, and limits
Who: Kisspeptin 112-121 (the 10-amino-acid form, kisspeptin-10). 12 healthy adults, 6 women and 6 men, each given a single dose, with blood oxytocin measured over the next hour. No placebo group. Run at Massachusetts General Hospital and Harvard, USA.
A new use under study: a possible test for oxytocin deficiency (low levels of the hormone oxytocin, seen in some people with a pituitary condition). Ten minutes after kisspeptin, oxytocin rose 18.8% from baseline (p = 0.004), more in men (31.9%) than in women (5.7%). The authors suggest kisspeptin could become a test for oxytocin deficiency in men.
Read with care: Very small, single dose, no placebo, healthy people only; it has not been tried in patients with oxytocin deficiency. Several authors hold patents or company interests, including one with a financial interest in SeNa Therapeutics, which develops reproductive treatments.
- Human trial2024
Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical trials
MVT-602 was absorbed and cleared quickly, with a half-life of 1.3 to 2.2 hours, but the LH rise it produced lasted far longer than the drug itself: the average peak rise was 82.4 units per litre at about 24.8 hours, and LH stayed above 15 units per litre for 33 hours.
Full finding, who was studied, and limits
Who: A DIFFERENT MOLECULE, not kisspeptin itself. MVT-602 is a man-made drug designed to act on the same receptor and last longer. 24 healthy women aged 18 to 35 in the phase 1 trial, and 75 healthy women having ovarian stimulation in the phase 2a trial (16 to 17 per MVT-602 group, 5 on an active comparator, 5 on placebo).
MVT-602 was absorbed and cleared quickly, with a half-life of 1.3 to 2.2 hours, but the LH rise it produced lasted far longer than the drug itself: the average peak rise was 82.4 units per litre at about 24.8 hours, and LH stayed above 15 units per litre for 33 hours. Ovulation happened within 5 days in 75% to 100% of women on MVT-602, 100% on the comparator and 60% on placebo. The authors said MVT-602 was safe and well tolerated across the range tested. An earlier study from the same collaboration found MVT-602 kept GnRH nerve cells firing for 115 minutes against 55 minutes for kisspeptin-54.
Read with care: This is not kisspeptin. It is a receptor agonist, developed by Myovant Sciences, with different handling in the body. The trials were in healthy women, not in patients being treated for anything, and we found no published later-stage trial or any sign that the programme has produced an approved product.
- Human trial2023
Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
Whole-brain activity differed from placebo with an average effect size (Cohen d) of 0.81 (95% confidence interval 0.41 to 1.21; P equals 0.003).
Full finding, who was studied, and limits
Who: 37 right-handed heterosexual men with hypoactive sexual desire disorder were randomised; 32 completed. Average age 37.9. Double-blind, placebo-controlled, two-way crossover.
Whole-brain activity differed from placebo with an average effect size (Cohen d) of 0.81 (95% confidence interval 0.41 to 1.21; P equals 0.003). Penile swelling was up to 56% greater than on placebo (mean difference 0.28 units, 95% confidence interval 0.04 to 0.52; P equals 0.02). Self-rated happiness about sex was higher (mean difference 0.63 points, 95% confidence interval 0.10 to 1.15; P equals 0.02).
Read with care: Thirty-seven men, a single exposure in a laboratory. The confidence interval on the physical measure only just excludes no effect. There is no evidence that any of this persists, and no trial has tested kisspeptin as a treatment for low desire over time.
- Human trial2022
Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
Brain scans during erotic videos showed changes in several regions compared with placebo: less activity in the left inferior frontal gyrus (P equals 0.01), more in the right postcentral and supramarginal gyrus (P less than 0.001) and less in the right temporoparietal junction (P equals 0.02).
Full finding, who was studied, and limits
Who: 40 premenopausal women with hypoactive sexual desire disorder (persistent low sexual desire that causes distress) were randomised; 32 completed both visits. Average age 29.2. Randomised, double-masked, placebo-controlled, two-way crossover.
Brain scans during erotic videos showed changes in several regions compared with placebo: less activity in the left inferior frontal gyrus (P equals 0.01), more in the right postcentral and supramarginal gyrus (P less than 0.001) and less in the right temporoparietal junction (P equals 0.02). Hippocampal activity tracked how distressed women were about their sexual function at the start (r equals 0.469, P equals 0.007), and posterior cingulate activity tracked reduced sexual aversion (r equals 0.476, P equals 0.005). Kisspeptin was well tolerated with no reported adverse effects.
Read with care: Forty women, one dose on one occasion, with brain activity as the main measure. The trial did not test whether desire improved over weeks or months, and it was not designed to show that kisspeptin treats the condition.
- Human trial2017
Kisspeptin modulates sexual and emotional brain processing in humans
Kisspeptin increased activity in limbic parts of the brain, the areas involved in emotion and reward, when the men were shown sexual and couple-bonding images.
Full finding, who was studied, and limits
Who: 29 healthy heterosexual young men, given kisspeptin and, separately, a vehicle (inactive) infusion, while having their brains scanned with functional MRI and completing mood and attitude questionnaires.
Kisspeptin increased activity in limbic parts of the brain, the areas involved in emotion and reward, when the men were shown sexual and couple-bonding images. The size of that change tracked questionnaire scores for reward, drive, mood and sexual aversion. Kisspeptin also reduced negative mood.
Read with care: Twenty-nine healthy men, scanned on two occasions. The abstract we read does not state whether the study was randomised or blinded. Brain activity on a scan is not the same as behaviour or symptoms, and no numbers are given in the abstract.
- Human trial2015
Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy
Eggs matured in 95% of the women.
Full finding, who was studied, and limits
Who: 60 women at high risk of ovarian hyperstimulation syndrome, a dangerous over-response to IVF drugs. Phase 2, multi-dose, open-label, randomised trial with an adaptive design.
Eggs matured in 95% of the women. Across all groups, among the 51 women who had an embryo transfer, 63% had a positive pregnancy test, 53% a clinical pregnancy and 45% a live birth. In the best-performing group those figures were 85%, 77% and 62%. No woman developed moderate, severe or critical ovarian hyperstimulation syndrome.
Read with care: Open-label, meaning everyone knew what was being given, and there was no control group receiving the standard trigger. Sixty women at one centre. The OHSS result is encouraging but a trial of this size cannot rule out an uncommon problem, and this remains the high point of kisspeptin research rather than a settled result.
- Human trial2014
Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization
Eggs matured at every amount tested.
Full finding, who was studied, and limits
Who: 53 women having IVF, after their ovaries had been stimulated in the usual way. A single injection of kisspeptin-54 under the skin was used instead of the usual trigger injection to make the eggs complete their final maturation.
Eggs matured at every amount tested. Fertilisation and embryo transfer went ahead in 92% of the women (49 of 53). 40% (21 of 53) had a positive pregnancy test, and 23% (12 of 53) had a clinical pregnancy (a pregnancy confirmed on a scan).
Read with care: This was a first-in-patients study, not a randomised comparison with the standard trigger, so the pregnancy figures cannot be compared with normal IVF success rates. One centre, one team. Egg maturation is a step in the process, not a baby.
- Human trial2014
Exogenous kisspeptin administration as a probe of GnRH neuronal function in patients with idiopathic hypogonadotropic hypogonadism
An important negative result.
Full finding, who was studied, and limits
Who: 12 people: 11 with congenital idiopathic hypogonadotropic hypogonadism (9 men, 2 women) and 1 man whose condition had reversed. Blood was sampled every 10 minutes after kisspeptin and after GnRH, before and after six days of GnRH treatment.
An important negative result. Everyone whose condition persisted had no LH response at all to kisspeptin, across several different genetic causes. Only the man whose hypogonadotropism had reversed responded strongly. The authors concluded that the GnRH nerve-cell network is impaired in these patients, possibly because it was never fully engaged during puberty.
Read with care: Twelve people. It tells us kisspeptin does not work as a treatment for this group, which is the group most often invoked when kisspeptin is sold as a hormone booster. It does not tell us about people with a normally functioning axis.
- Human trial2011
Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
A single injection of kisspeptin-10 into a vein raised LH from 4.1 to 12.4 units per litre at 30 minutes (P less than 0.001).
Full finding, who was studied, and limits
Who: Healthy men. Six men in the single-injection part; four men per group in the infusion parts, with infusions lasting up to 22.5 hours.
A single injection of kisspeptin-10 into a vein raised LH from 4.1 to 12.4 units per litre at 30 minutes (P less than 0.001). Notably, the largest amount tested produced a smaller response than a lower amount (P less than 0.05), which is a sign that the system can be overloaded. During a 22.5-hour infusion, LH rose from 5.4 to 20.8 units per litre and testosterone from 16.6 to 24.0 (P less than 0.001). A lower-rate infusion increased the frequency of LH pulses from 0.7 to 1.0 per hour (P less than 0.05).
Read with care: Four to six men per arm. The finding that more is not better matters: it means a simple 'more raises testosterone more' picture is wrong. No clinical outcome was measured and the abstract reports no side-effect data.
- Human trial2011
The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans
In men, kisspeptin-10 raised LH and FSH.
Full finding, who was studied, and limits
Who: 35 healthy women and 11 healthy men (4 to 5 per group), given kisspeptin-10 into a vein, under the skin, or as an infusion.
In men, kisspeptin-10 raised LH and FSH. In women in the first half of the cycle, it did nothing at all: no rise in LH or FSH after any of the three ways of giving it, even at the highest amounts tested. In women just before ovulation, it did raise LH and FSH. The same study measured the half-life of kisspeptin-10 in blood as about 4 minutes (3.8 minutes in men, 4.1 minutes in women), which is roughly seven times shorter than kisspeptin-54. Testosterone was not consistently stimulated in men.
Read with care: Four to five people per group. The important negative result, no response at all in women during the follicular phase, is easy to miss. The study was a physiology experiment, not a treatment trial.
- Human trial2009
Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis
This is the study that defines the main limitation of kisspeptin as a treatment.
Full finding, who was studied, and limits
Who: 10 women with hypothalamic amenorrhoea (periods have stopped because the brain's reproductive signal has shut down, often after weight loss, heavy exercise or stress), 5 per group. Prospective, randomised, double-blinded, parallel-group: kisspeptin-54 or salt water injected under the skin twice a day for two weeks.
This is the study that defines the main limitation of kisspeptin as a treatment. On day 1 the average maximum rise over four hours was 24.0 units per litre for LH and 9.1 for FSH. By day 14 those rises had collapsed to 2.5 for LH and 0.5 for FSH (both P less than 0.05). The women still responded normally to GnRH afterwards, so the pituitary had not failed; the response to kisspeptin itself had worn off. There was no significant change in LH pulsatility or in ultrasound measures of reproductive activity over the two weeks.
Read with care: Ten women in total. But the direction of the result is the point: giving kisspeptin repeatedly in this pattern stopped working within two weeks and produced no measurable change on ultrasound.
- Human trial2007
Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women
Kisspeptin-54 injected under the skin raised LH, and how much it raised it depended entirely on where the woman was in her cycle.
Full finding, who was studied, and limits
Who: Healthy women with regular menstrual cycles: 3 to 4 women at each of seven injection levels in a dose-finding part, and 8 women in a part that compared kisspeptin-54 with salt water at different points in the cycle.
Kisspeptin-54 injected under the skin raised LH, and how much it raised it depended entirely on where the woman was in her cycle. The rise in LH above baseline averaged 0.12 units per litre in the follicular phase (the first half of the cycle), 20.64 in the preovulatory phase (just before the egg is released; P less than 0.001 compared with follicular) and 2.17 in the luteal phase (P less than 0.01 compared with follicular).
Read with care: Small numbers in each group. It measures a hormone response over hours, not ovulation, pregnancy or any symptom. It also means results in women cannot be generalised without saying when in the cycle they were obtained.
- Human trial2005
Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males
This was the first study to give kisspeptin to people.
Full finding, who was studied, and limits
Who: 6 healthy male volunteers. Double-blind, placebo-controlled crossover: each man received a 90-minute infusion of kisspeptin-54 into a vein and, on another occasion, salt water, in random order.
This was the first study to give kisspeptin to people. Averaged over 90 minutes, LH was 10.8 units per litre on kisspeptin against 4.2 on salt water, and FSH was 3.9 against 3.2 (both P less than 0.001). Testosterone averaged over three hours was also higher on kisspeptin (P less than 0.001). The half-life of kisspeptin-54 in the blood was 27.6 minutes, plus or minus 1.1.
Read with care: Six men, one short infusion each. It shows the hormone system responds, nothing more. No measure of fertility, symptoms or anything a patient would notice, and no information in the abstract about side effects.
- Human trial2003
Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54
All five affected siblings carried two copies of a 155-nucleotide deletion in the GPR54 gene, the receptor that kisspeptin acts on.
Full finding, who was studied, and limits
Who: One large family whose parents were related, with five siblings who had isolated hypogonadotropic hypogonadism (the reproductive hormone system never switched on, so puberty did not happen). Relatives were also tested.
All five affected siblings carried two copies of a 155-nucleotide deletion in the GPR54 gene, the receptor that kisspeptin acts on. The deletion removed a splice site and part of one exon, so the receptor could not be made properly. Unaffected family members had either no copy or one copy. The authors concluded that losing this receptor causes the condition, and that the receptor and its kisspeptin partner play a major and previously unsuspected role in the reproductive hormone axis.
Read with care: This is a genetic study of one family, not a trial of a treatment. It shows that the kisspeptin signal is needed for puberty. It says nothing about what happens when extra kisspeptin is given to someone whose system already works.
- Human trial2003
The GPR54 gene as a regulator of puberty
The unrelated patient carried two different faulty copies of GPR54 (R331X and X399R).
Full finding, who was studied, and limits
Who: A family whose parents were related, in which affected members carried two copies of a mutation called L148S, plus one unrelated patient. That patient was compared with six people who had idiopathic hypogonadotropic hypogonadism without any GPR54 mutation. The paper also studied mice bred without a working Gpr54 gene.
The unrelated patient carried two different faulty copies of GPR54 (R331X and X399R). In laboratory cells, the mutated receptors produced much less signal than normal ones. The patient made less of his own GnRH than the comparison patients. Mice without a working Gpr54 gene had the same condition: small testes in males, no follicle maturation and delayed vaginal opening in females, with normal hypothalamic GnRH levels and a normal response to injected gonadotropins or GnRH. The authors concluded that this receptor is essential for normal GnRH physiology and for the onset of puberty.
Read with care: Again a genetics paper, published the same month as the Paris one, not a treatment study. The mouse results support the human ones but the abstract gives no group sizes. The journal's full text could not be opened.
New England Journal of Medicine 2003;349(17):1614-1627 · pubmed.ncbi.nlm.nih.gov
Safety findings
- FDA's 2024 review counted roughly 300 people who had been given kisspeptin-10 in published studies, by vein or under the skin, and reported that no serious adverse events were reported in them. It added immediately that these studies were short, small, and often did not report adverse events at all. In the single-injection studies the longest run of use was hourly for 11 hours in one day; in the infusion studies, 24 hours. Many studies gave only one or two injections. Source: fda.gov
- No published trial has assessed the safety of kisspeptin-10 given long term or on a fixed schedule for more than a day, according to the same FDA review. FDA also found no study at all that gave kisspeptin-10 to humans by injection into muscle, one of the two routes it was nominated for, and only a single study that gave one injection under the skin, to about 35 healthy women, in which safety outcomes were not reported. Source: fda.gov
- Immunogenicity is FDA's main stated safety concern: an injected peptide of this length may provoke an immune reaction, which could range from antibodies with no effect to serious reactions, and antibodies raised against synthetic kisspeptin-10 could cross-react with and neutralise the body's own kisspeptin. FDA found no study that had formally investigated this. It also raised peptide-related impurities, aggregation and the fact that the nomination gave no information on individual impurities. Source: fda.gov
- One report in FDA's adverse event reporting system (FAERS case 17637978), searched through October 2023. A 17-year-old male with hypogonadotropic hypogonadism was given a compounded kisspeptin-10 product injected under the skin daily for six weeks, with the aim of raising testosterone. He gained weight and his estrone (an oestrogen) rose, neither of which was wanted. FDA notes the report has an unclear temporal relationship and insufficient information, and that a single report cannot show cause. Source: fda.gov
6 more safety findings
- Loss of effect rather than harm, but it matters: in 10 women with hypothalamic amenorrhoea given kisspeptin-54 under the skin twice daily, the hormone response was largely gone by day 14. In healthy men, a continuous 5-day infusion of kisspeptin-10 ended with gonadotropin levels no different from vehicle. Source: pubmed.ncbi.nlm.nih.gov
- Animal and cell findings that have not been resolved: in laboratory experiments on human blood-vessel cells, high concentrations of kisspeptin-10 increased inflammation markers and the stickiness of immune cells, and in mice bred to develop atherosclerosis, four weeks of continuous kisspeptin-10 accelerated plaque formation, with no safe level identified in that study. FDA notes the concentrations used in the cell work were about 7,400 times higher than blood levels measured in healthy volunteers, so the relevance to people is unknown. Separately, a 14-day study in dogs found no drug-related effects. Source: fda.gov
- FDA identified no studies of genotoxicity (damage to DNA), no developmental or reproductive toxicity studies, and no cancer studies for kisspeptin-10, and concluded that the animal safety studies available were too limited in scope and duration to inform clinical use. Source: fda.gov
- In the IVF trial of 60 women at high risk of ovarian hyperstimulation syndrome, no woman developed moderate, severe or critical ovarian hyperstimulation syndrome. This is the clearest positive safety signal in the kisspeptin literature, from a single open-label trial. Source: pubmed.ncbi.nlm.nih.gov
- In the crossover trial in 40 premenopausal women with hypoactive sexual desire disorder, the authors reported that kisspeptin was well tolerated with no adverse effects. Source: pubmed.ncbi.nlm.nih.gov
- Nothing is known about the safety of products sold online. FDA's review notes that websites of compounding pharmacies, med spas and clinics market kisspeptin for fertility, weight loss and 'regulating hormonal pathways', that some sell it as a research product, and that it is often unclear whether these are kisspeptin-10 or a salt or ester of it. Source: fda.gov
Rules and status
Not approved. No kisspeptin medicine has been approved by the FDA or, as far as FDA could determine, by any other country's regulator. Kisspeptin-10 sits in FDA's 'Category 2' table of bulk drug substances that may present significant safety risks when used in compounding.
The full history, with dates
Kisspeptin-10 appears in the Category 2 table on FDA's page 'Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks' (content current as of 22 April 2026, checked 18 November 2026). It was added to that table on 29 September 2023. FDA's stated reason, quoted from that page: 'Compounded drugs containing Kisspeptin-10 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.' Kisspeptin-10 is not in the 'nominated but withdrawn' table. There is a dedicated FDA advisory committee briefing document: 'Evaluation of Kisspeptin-10 for Inclusion on the 503A Bulk Drug Substances List', dated 5 July 2024, prepared for the Pharmacy Compounding Advisory Committee meeting of 29 October 2024. It was nominated by Wells Pharmacy Network for the treatment of secondary hypogonadism in men. FDA concluded: 'we propose not adding kisspeptin-10 to the 503A Bulks List', on the grounds that it is not well characterised, that information on immunogenicity risk is lacking, that there is insufficient evidence of effectiveness, and that approved drugs exist for the condition. At the meeting the committee voted 0 yes, 11 no, 0 abstentions against placing kisspeptin-10 on the list; the minutes record that 'the committee unanimously agreed that Kisspeptin-10 should not be included on the 503A Bulks List due to the lack of convincing safety and efficacy data.' On 30 October 2026 HHS published a Federal Register notice (91 FR 68526) of a draft, non-binding interim enforcement-discretion policy for 503A compounding with certain peptides. The notice itself names no peptides and points to an appendix on hhs.gov. Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Kisspeptin is not among them. We found no kisspeptin document among the materials for the July 2026 advisory committee meeting.
Source: fda.gov (source dated 2026-04-22)
In sport: Prohibited. Kisspeptin is named in class S2 (Peptide hormones, growth factors, related substances, and mimetics), under heading S2.2.1, 'Testosterone-stimulating peptides in males including, but not limited to', where the entry reads 'kisspeptin and its agonist analogues'. The same heading covers chorionic gonadotrophin, luteinizing hormone, and GnRH and its agonist analogues. The wording is the same in the 2026 List (in force from 1 January 2026) and the 2027 List (published 21 September 2026, in force from 1 January 2027). S2 substances are prohibited at all times, in and out of competition, and the 2026 List states they are non-Specified Substances. Because the heading says 'in males', the entry as written applies to male athletes. This is a named entry, so class S0 (non-approved substances) does not need to be relied on. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| Kisspeptin is a natural testosterone booster. | In healthy men a single injection raises LH and FSH within minutes, and in one study a long infusion raised testosterone. But in the Imperial study of kisspeptin-10 in men, testosterone was not consistently stimulated, and in another study a larger single injection produced a smaller LH response than a smaller one. In men whose reproductive axis has failed, kisspeptin produced no response at all. No trial has shown that kisspeptin treats low testosterone, and FDA concluded there is insufficient evidence to draw any conclusion on effectiveness for secondary hypogonadism in men. Source: fda.gov |
| Keep taking it and it keeps working. | It does not. In 10 women given kisspeptin-54 twice daily, the LH rise fell from 24.0 units per litre on day 1 to 2.5 on day 14, and the FSH rise from 9.1 to 0.5. In healthy men, a continuous 5-day infusion of kisspeptin-10 ended with gonadotropins no different from vehicle. Researchers call this tachyphylaxis and it is one of the best-replicated findings about kisspeptin, seen in monkeys as well as people. Source: pubmed.ncbi.nlm.nih.gov |
| Kisspeptin-10 is the same thing as the kisspeptin used in the famous studies. | Different molecule and very different behaviour. Kisspeptin-54 has a half-life in blood of about 28 minutes; kisspeptin-10 about 4 minutes. The IVF trigger trials, the hypothalamic amenorrhoea studies and the first human studies all used kisspeptin-54. Kisspeptin-10 is the form usually sold. Source: pubmed.ncbi.nlm.nih.gov |
| It is a proven fertility treatment. | It is an experimental egg-maturation trigger studied in two trials at one London centre, 53 and then 60 women, both open-label and neither compared head-to-head with the standard trigger. The results were promising, including no moderate or worse ovarian hyperstimulation syndrome in the high-risk trial. That is a reason for larger trials, not a treatment anyone can get. Source: pubmed.ncbi.nlm.nih.gov |
| Kisspeptin increases sexual desire. | Two small crossover trials in people with hypoactive sexual desire disorder, 40 women and 37 men, found changes in brain activity on scans, and in men a modest increase in penile swelling and in self-rated happiness about sex. Each person received a single exposure in a laboratory. Neither trial tested whether desire improved over days or weeks, and neither was designed to show kisspeptin treats the condition. Source: pubmed.ncbi.nlm.nih.gov |
| It helps with weight loss. | No human evidence. FDA's review specifically records clinic websites claiming kisspeptin-10 breaks down fat and improves body composition, and notes that weight loss and fertility are the most common uses advertised. None of the human studies FDA reviewed measured weight loss. The one adverse event report FDA holds describes unwanted weight gain. Source: fda.gov |
| It is safe because the body already makes it. | Being natural does not make an injected copy safe. FDA found no study of immunogenicity, no genotoxicity, reproductive or cancer studies, and no safety data for the routes it was nominated for. Antibodies raised against injected kisspeptin-10 could in principle neutralise the body's own kisspeptin. Cell and mouse work has also raised an unresolved question about artery disease. Source: fda.gov |
| Selling it as 'research use only' makes it legal. | FDA's advisory committee voted 0 to 11 against allowing kisspeptin-10 in pharmacy compounding, and FDA keeps it in the Category 2 table of substances that may present significant safety risks. FDA's own review notes websites marketing kisspeptin-10 as a research product. The label does not change the substance's regulatory status. Source: fda.gov |
What a genuine lab report should show
- Which form is in the vial. A report that just says 'kisspeptin' is not enough: kisspeptin-10 and kisspeptin-54 are different molecules with very different handling in the body. The report should name the form, and the mass result should match it (about 1302 Da for kisspeptin-10, about 5857 g/mol for kisspeptin-54).
- Identity by mass spectrometry, not purity alone. FDA's review of a supplier's certificate for kisspeptin-10 shows exactly what a real one looks like: a measured mass of 1302.5 Da against a specification of 1302.5 plus or minus 1.0.
- The C-terminal amide. Both forms end in an amide rather than a free acid, and that ending is part of what makes them active. A genuine certificate states the modification.
- Purity by HPLC with the actual chromatogram trace, the method and the test date, not just a percentage.
- Peptide content tested separately from purity. These are different numbers and the gap can be large: in the certificate reproduced in FDA's review, purity was 98.9% while peptide content was 90.0%. A report giving only purity tells you nothing about how much peptide is actually in the vial.
- Impurity detail. FDA's central criticism of kisspeptin-10 was that nobody could say what the individual peptide-related impurities, variants and aggregates are. A certificate that gives only a total impurity limit does not answer that.
- Bacterial endotoxin and water content, which the example certificate in FDA's review reports.
- Traceability: a named independent laboratory, a lot or batch number matching the label, a date, and a result you can confirm with the laboratory directly.
- A clean certificate describes one tested sample. It does not make the substance an approved medicine and says nothing about whether it is safe in people.
What is not known
- Whether kisspeptin does anything useful as a treatment at all. Every positive human result is either a short-term hormone measurement, a brain scan, or an early IVF trial at one centre.
- Whether the IVF trigger work has gone further. The largest published trial was 60 women in 2015. We did not find a published randomised comparison against the standard trigger, and the editor should check whether one has since appeared.
- The right pattern of exposure. Continuous exposure stops working; twice-daily stops working within two weeks; twice-weekly and an on-off daily pattern work better but still fade. Nobody has established a schedule that keeps working.
- Long-term safety is simply unknown. The longest published human study ran 12 days.
- The artery-disease signal. Cell experiments and a mouse study found kisspeptin-10 promoted atherosclerosis; FDA noted the concentrations were roughly 7,400 times higher than human blood levels and said the clinical relevance remains to be determined.
- Immunogenicity. No study has formally looked at whether injected kisspeptin-10 provokes antibodies, or whether those antibodies would attack the body's own kisspeptin.
- The sources disagree on the length of the KISS1 precursor protein: FDA's review says 145 amino acids, UniProt's reviewed human entry gives 138. This does not change the kisspeptin-54 or kisspeptin-10 sequences but should be checked before the page states a number.
- Whether MVT-602, the kisspeptin receptor agonist, is still in development. We found published phase 1 and phase 2a trials in healthy women and nothing later.
- Whether any regulator anywhere has approved a kisspeptin product since FDA's 2024 search of the global EDGE database found none. A negative cannot be proven from searching.
- What is actually in products sold as kisspeptin online. No independent analysis of marketed products was found.
Sources
All 35 sources
- de Roux et al. 2003, GPR54 loss of function (PubMed). pubmed.ncbi.nlm.nih.gov
- Seminara et al. 2003, GPR54 as a regulator of puberty, NEJM (PubMed). pubmed.ncbi.nlm.nih.gov
- Dhillo et al. 2005, first human study of kisspeptin-54 in men (PubMed). pubmed.ncbi.nlm.nih.gov
- Dhillo et al. 2007, kisspeptin-54 across the menstrual cycle (PubMed). pubmed.ncbi.nlm.nih.gov
- George et al. 2011, kisspeptin-10 and LH pulse frequency in men (PubMed). pubmed.ncbi.nlm.nih.gov
- Jayasena et al. 2011, kisspeptin-10 sexual dimorphism and pharmacokinetics (PubMed). pubmed.ncbi.nlm.nih.gov
- Jayasena et al. 2009, tachyphylaxis with chronic kisspeptin-54 (PubMed). pubmed.ncbi.nlm.nih.gov
- Jayasena et al. 2010, twice-weekly kisspeptin-54 for 8 weeks in hypothalamic amenorrhoea (PubMed). pubmed.ncbi.nlm.nih.gov
- Jayasena et al. 2014, increasing LH pulsatility in hypothalamic amenorrhoea (PubMed). pubmed.ncbi.nlm.nih.gov
- Yeung et al. 2026, chronic subcutaneous kisspeptin-10 for 12 days in healthy men (PubMed). pubmed.ncbi.nlm.nih.gov
- Naveed et al. 2026, continuous kisspeptin infusion and LH in healthy men (PubMed). pubmed.ncbi.nlm.nih.gov
- Jayasena et al. 2014, kisspeptin-54 egg maturation trigger in IVF, JCI (PubMed). pubmed.ncbi.nlm.nih.gov
- Abbara et al. 2015, kisspeptin-54 trigger in women at high OHSS risk (PubMed). pubmed.ncbi.nlm.nih.gov
- Chan et al. 2014, kisspeptin as a probe of GnRH neuronal function in IHH (PubMed). pubmed.ncbi.nlm.nih.gov
- Chan et al. 2012, kisspeptin administration to women across the menstrual cycle (PubMed). pubmed.ncbi.nlm.nih.gov
- Comninos et al. 2017, kisspeptin and sexual and emotional brain processing (PubMed). pubmed.ncbi.nlm.nih.gov
- Thurston et al. 2022, kisspeptin in women with hypoactive sexual desire disorder, JAMA Network Open (PubMed). pubmed.ncbi.nlm.nih.gov
- Mills et al. 2023, kisspeptin in men with hypoactive sexual desire disorder, JAMA Network Open (PubMed). pubmed.ncbi.nlm.nih.gov
- Abbara et al. 2020, kisspeptin receptor agonist MVT-602 compared with kisspeptin-54, JCI (PubMed). pubmed.ncbi.nlm.nih.gov
- MVT-602 phase 1 and phase 2a trials, Fertility and Sterility 2024 (PubMed). pubmed.ncbi.nlm.nih.gov
- Koysombat et al. 2025, kisspeptin and neurokinin B review, Physiological Reviews (PubMed). pubmed.ncbi.nlm.nih.gov
- FDA briefing document: Evaluation of Kisspeptin-10 for Inclusion on the 503A Bulk Drug Substances List, 5 July 2024. fda.gov
- FDA Pharmacy Compounding Advisory Committee, 29 October 2024, final summary minutes (kisspeptin-10 vote). fda.gov
- FDA Pharmacy Compounding Advisory Committee meeting page, 29 October 2024. fda.gov
- FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 table; content current as of 22 April 2026). fda.gov
- HHS notice, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526, 30 October 2026 (govinfo). govinfo.gov
- WADA 2026 Prohibited List, valid 1 January 2026 (kisspeptin named at S2.2.1). wada-ama.org
- PubChem compound record, kisspeptin-10, CID 25240297. pubchem.ncbi.nlm.nih.gov
- PubChem compound record, kisspeptin-54 / metastin, CID 71306396. pubchem.ncbi.nlm.nih.gov
- UniProt Q15726 (KISS1_HUMAN), with kisspeptin-54, -14, -13 and -10 marked as peptide features. uniprot.org
- WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
- Mills 2025: intranasal kisspeptin-54 study, LH rose in 34 people (eBioMedicine). pubmed.ncbi.nlm.nih.gov
- Mills 2025: kisspeptin-54 did not change anxiety in 95 healthy adults (JCEM). pubmed.ncbi.nlm.nih.gov
- Galbiati 2025: kisspeptin-10 raised oxytocin in 12 healthy adults. pubmed.ncbi.nlm.nih.gov
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.